Aditya Bardia, MD, MPH, FASCO, discusses how fam-trastuzumab deruxtecan-nxki compares with physician’s choice of chemotherapy in estrogen receptor-positive/HER2-low breast cancer.

The Toxicities and Adverse Effects That Emergency Physicians Must Know,” published in the December 2024 issue of Emeregency ...

Investigators from the UCLA Health Jonsson Comprehensive Cancer Center will discuss the latest clinical breakthroughs and research at the San ...

台康生技(6589)今(10)日公告乳癌生物相似药EG12014(Trastuzumab Biosimilar, also called EGI2014)FDA药证申覆未通过，查厂结果充填厂仍需改善。台康生技今日股价开盘直接锁在跌停板82.9元，至10:40，超过2800张的卖 ...

The new HER2-low category is exposing the limitations of IHC testing, challenging pathologists, and has oncologists ...

The proposed pertuzumab biosimilar QL1209 demonstrated equivalent efficacy and safety to reference pertuzumab (Perjeta) in ...

A significant breakthrough in breast cancer research has uncovered a key mechanism driving cancer invasion and drug ...

A University of Liverpool study reveals how two critical molecules present in 'HER2-positive' breast cancer - one of the most ...

New research uncovers key insights into breast cancer progression and drug resistance, paving the way for more effective ...

The government's drug funding agency Pharmac is asking for public feedback on its proposal to fund four new medicines for ...

A significant advance in breast cancer research has uncovered a key mechanism driving cancer invasion and drug resistance. A ...

A remarkable development in breast cancer research has revealed a fundamental mechanism behind driving cancer invasion and ...